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Abstract. A growth regulatory factor, which reversibly 
inhibits DNA synthesis and proliferation of fibro- 
blasts, has been isolated from medium conditioned by 
exposure to density-inhibited mouse 3T3 cells. This 
factor, termed FGR-s (13K), yielded a single polypep- 
tide (Mr 13,000) when analyzed by SDS PAGE under 
both reducing and nonreducing conditions. The dose- 
response curve of growth inhibition by FGR-s (13K) 
showed that 50% inhibition of 3T3 cell proliferation 
was achieved at a concentration of-3  ng/ml, corre- 
sponding to -0.23  nM. The activity of FGR-s (13K) 
was depleted by passing the material over an affinity 
column containing the monoclonal antibody 2A4; this 
monoclonal antibody had been previously character- 
ized to bind to the Mr 13,000 polypeptide. These re- 
suits indicate that we have purified a growth regula- 
tory factor that acts to inhibit the proliferation of cells 
in an autocrine pathway. 
T 
HE mouse 3T3 fibroblast line exhibits a form of  growth 
control  in  vitro  in  that the  cells  reach  only a  low 
saturation density and can remain for long periods in 
a viable, monolayer state (21, 22). Treatment of sparse, pro- 
liferating cultures of 3T3 cells with medium conditioned by 
exposure  to  density-inhibited 3T3  cultures  resulted  in  an 
inhibition of growth and division in the target cells as com- 
pared with similar treatment with unconditioned medium 
(20). This inhibitory activity was fractionated, yielding one 
preparation that exhibited reversible inhibition of growth and 
direct interactions with target 3T3 cells (19, 25). This fraction, 
designated fibroblast  growth regulator, soluble  form (FGR- 
s), ~ contained  two  major  polypeptides  (Mr's  10,000 and 
13,000) (19, 27). Using  similar procedures,  Wells and Mal- 
lucci have shown that secondary cultures of mouse embryo 
fibroblasts release into the medium a growth inhibitory activ- 
ity whose  polypeptide  composition  and  physiocochemical 
behavior closely parallel those of FGR-s (28). 
More  recently,  we  have  generated  and  characterized  a 
monoclonal antibody (antibody 2A4)  that  neutralized the 
activity of FGR-s (8). This monoclonal antibody specifically 
bound the Mr  13,000 polypeptide, hereafter designated as 
FGR-s (13K). Based on these data, we concluded that FGR-s 
(13K) is responsible  for at least part of the observed  growth 
inhibitory activity.  This assignment of biological  activity to 
FGR-s  (13K)  does  not  exclude  the  possibility  that  other 
components of the FGR-s fraction (e.g. Mr  10,000 polypep- 
tide) may also be biologicaly active. Moreover, we could not 
,4hl,z,  vialions used in this paper. DME, Dulbecco's modified Eagle's medium; 
FGR-s. fibroblast growth regulator, soluble form: TGF-¢~, transforming growth 
factor-~L 
ascertain whether FGR-s (13K) was active independent of the 
presence  of other polypeptides (8, 26). In the present com- 
munication, we report the purification to apparent homoge- 
neity of FGR-s (13K) on a preparative scale. This has allowed 
us to assay the individual polypeptide for biological activity. 
Materials and Methods 
Cell Culture and Preparation of  FGR-s 
Swiss 3T3  cells (American Type Culture Collection, CCL 92) were grown at 
37°C  in  Dulbecco's  modified  Eagle's medium  (DME,  KC  Biological Inc., 
Lenexa, KS) containing 10% calf serum (Microbiological Associates. Walkers- 
ville, MD).  The  detailed  protocol  for  the  preparation  of FGR-s  has  been 
described (19,  20).  In  brief, confluent monolayers of 3T3  cells were washeo 
twice with DME;  fresh, serum-free DME was then added to the cultures (10 
ml/150 cm  2 of growth area). After an overnight incubation, the medium was 
collected as serum-free conditioned medium. This medium was centrifuged at 
1,470 g  for  10 min and the supernatant was subjected to ammonium sulfate 
precipitation (80%  of saturation at  room  temperature).  The precipitate was 
redissolved in 5  mM  Tris, pH  8.0 (2.5  ml of buffer per liter of conditioned 
medium) and fractionated by Sephadex G-50 chromatography (1.4 x  110 cm) 
in the same buffer. The material eluting at a position corresponding to poly- 
peptides of molecular weight 10,000 to 15,000 was pooled as the FGR-s fraction. 
FGR-s labeled with [3~Slmethionine was prepared as described, using 100 
•Ci  of radioactive methionine per  ml  (I,014  Ci/mmol,  Amersham  Corp., 
Arlington Heights, IL) and DME containing unlabeled melhionine at 3 ug/ml 
(one tenth of the concentration normally found in DME) (19). 
Ion-Exchange Chromatography on DEAE-Cellulose 
A column (0.8  x  2 cm) of DEAE-cellulose (Pharmacia Fine Chemicals, Pisca- 
taway, N J)  was equilibrated with 5  mM  Tris,  pH  8.0.  The  pooled material 
corresponding to the FGR-s fraction of the Sephadex G-50 column (19) was 
applied to the ion-exchange column. After a wash with starting buffer, a gradient 
(0 to 0.5  M  NaCI in  100  ml of 5  mM Tris, pH  8.0) was used to develop the 
column.  1.7-ml fractions were collected. 
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The generation and characterization of hybridoma done 2A4 have been pre- 
viously described (8).  Rat spleen cells were immunized in vitro (12) with the 
FGR-s fraction. After 96 h of culture, the rat lymphocytes were fused with the 
mouse myeloma cell line NS-l-Ag4/l (NS-l line, Salk Institute), using polyeth- 
ylene glycol 1500 (5).  Hybridoma cultures that produced antibodies reacting 
with FGR-s were detected by the binding of rat immunoglobulin in the culture 
supernatants to FGR-s adsorbed onto lmmulon-2 plates (Dynatech Laborato- 
ries, Alexandria, VA) (8). 
The supernatant from hybridoma clone 2A4 was fractionated on an affinity 
column  of Affi-Gel  l0  (Bio-Rad  Laboratories,  Richmond,  CA)  covalently 
derivatized (9)  with rabbit antibodies directed against rat  immunoglobulin 
(Sigma Chemical Co.,  St.  Louis,  MO),  Material bound  to  the column was 
eluted with 0.1 M citrate buffer (pH 3.0). This material was a rat immunoglob- 
ulin designated as antibody 2A4 (8). 
Depletion of FGR-s (13K) over an Antibody 
2A4 Column 
Rabbit antibodies directed against rat immunoglobulin (40 rag) were coupled 
to Affi-Gel  10 (2 ml of beads) (9).  Supernatant (50 ml) from the hybridoma 
clone 2A4 was passed through the column (0.4 x  2.5 cm) three times. The 
supernatant of the parent myeloma NS-1  cell line was similarly passed through 
an identical column for controls. Material bound nonspecifically was removed 
by washing with 0.1  M  phosphate buffer (pH  8.0).  Finally, a  preparation of 
FGR-s (13K) (8 ng/ml, 2 ml) was percolated through either the antibody 2A4 
column or the NS-I control column. The activities  of the original FGR-s (13K) 
preparation, as well as the pooled flow-through fractions, representing material 
not bound by the respective  affinity columns, were assayed for growth inhibitory 
activity. 
Assays of  DNA Synthesis 
Target cells used to lest the growth inhibitory activity were routinely seeded at 
an  initial density  of  5  x  103  cells/cm  2  in  a  96-well  culture dish  (Costar, 
Cambridge, MA). For experiments in which the density of the target cells was 
varied, the cells were seeded at one  half the desired density. After overnight 
incubation, the cells were deprived of serum for 24 h. Then the medium was 
removed and  the  test  fraction  was added  (75  ul) along with  150  ul  DME 
containing 5% (vol/vol) calf serum. 
DNA synthesis was assayed 24 h later with a pulse of [3H]thymidine ( 1 uCi/ 
culture, 1.9 Ci/mmol, Schwarz-Mann. Spring Valley, NJ) for 3 h at 37°C. After 
the pulse, the radioactive medium was removed and the cells were washed three 
times with cold phosphate-buffered saline (PBS) and once with 10% trichloro- 
acetic acid. The cells were then solubilized with 0.2 ml of 1% SDS in 0.1  N 
NaOH. After incubation at 37°C for 10 rain, cell lysates were added to 2 ml of 
scintillation cocktail ( 1 g dimcthyl-1.4-bis[2-5-phenyloxazoly]benzene;  8 g 2.5- 
diphenyl-oxazole; 1.33  ml Triton X-100; and 2,666 ml of toluene) for scintil- 
lation counting. 
In  reversibility studies, cultures were treated with fractions derived from 
FGR-s.  After  22  h,  the  medium  was removed and  replaced with an  equal 
volume of fresh DME containing 5% (vol/vol) calf serum. DNA synthesis in 
these cultures was measured 16 and 42 h later. 
Assays of Cell Number and Cell Viability 
Cultures were treated with fractions derived from FGR-s or a control fraction. 
At various times thereafter, the cells were washed three times with PBS and 
were removed from  lhe growth surface by trypsin treatment. The cells were 
then centrifuged, resuspended in DME, diluted with trypan blue, and counted 
in a corpuscle counting chamber (Hausser Scientific, Blue Bell, PA) (20). 
The viability of cells treated with FGR-s-derived fractions was determined 
while the cells remained attached to the growth surface. After removal of growth 
medium, the cells were incubated with lrypan blue (0.08% wt/vol in PBS) for 
10 min at room temperature. The staining solution was then removed and the 
viable cells were counted using an Olympus inverted microscope. 
PAGE 
SDS PAGE was carried out according to the procedure of Laemmli (11), using 
10 or  16% acrylamide running gels and 5% acrylamide stacking gels. For gels 
electrophoresed under reducing conditions, 2-mercaptoethanol (4%,  vol/vol) 
was included in the sample buffer. The gels were fixed and stained with silver 
reagent (15). With radioactive samples, the gel was subjected to fluorography 
as described by Bonnet and Laskey (4) using Kodak X-Omat R (XAR-5) film. 
Results 
Ion-Exchange Chromatography of  FGR-s 
In  previous experiments,  we demonstrated that the growth 
inhibitory in conditioned medium of 3T3  cells can be frac- 
tionated by ammonium sulfate precipitation and gel filtration 
on Sephadex G-50 columns (19). The material eluting from 
the Sephadex G-50 column at a position corresponding to a 
molecular weight range of 10,000-15,000  showed enrichment 
in  specific  biological  activity  (growth inhibition  assay) and 
was designated FGR-s. Isoelectric focusing and PAGE analysis 
showed that the principal components of the FGR-s fraction 
were polypeptides of Mr 10,000 (pI ~7.5) and 13,000 (pI ~ 10) 
(27). 
Because the ampholines used to establish the pH gradient 
were toxic to the target 3T3 cells, we could not demonstrate 
growth inhibitory activity in the individual polypeptides.  Is- 
oelectric focusing did not appear, therefore, to be a promising 
preparative procedure for the purification of the inhibitory 
polypeptide. Nonetheless, the high isoelectric point of FGR-s 
(13K),  which was implicated by monoclonal antibody neu- 
tralization experiments to be at least partially responsible for 
growth inhibitory activity (8),  suggested ion-exchange chro- 
matography as a preparative procedure. 
To  carry  out  ion-exchange  chromatography,  two  minor 
modifications of the original procedure (19) for the prepara- 
tion of FGR-s were made. First, gel filtration on Sephadex G- 
50 columns was performed in 5 mM Tris, pH 8.0, instead of 
DME. This allowed the direct application of the effluent from 
the Sephadex column onto the ion-exchange column. Second, 
a wider range of fractions, centered approximately at FGR-s, 
was pooled and subjected to ion-exchange chromatography. 
The rationale for this was that we did not assay the individual 
fractions from the Sephadex G-50 column for activity or for 
polypeptide content (SDS gels). Therefore, the precise position 
corresponding to the FGR-s fractions was not determined and 
was compensated for by including material in fractions adja- 
cent to FGR-s. This allowed us to save material, which would 
have  been  used  in  the  assays,  and  to  save  time,  thereby 
minimizing losses of material due to adsorption to test tubes. 
DEAE-cellulose chromatography of a  [3SS]methionine-la- 
beled  preparation  of FGR-s  resulted  in  the  separation  of 
several components (components A-F,  Fig.  I b).  When  the 
fractions eluting from the ion-exchange column were assayed 
for growth inhibitory activity,  only component A  (Fig.  l b) 
exhibited activity; the remainder of the components failed to 
show any appreciable activity (Fig. 1 a). The sum of the growth 
inhibitory activity in component A  (Fig.  l b) accounted for 
~80%  of the total activity applied to the column. There was 
a  sixfold  enrichment  in  terms  of  specific  activity  in  this 
fractionation step. 
PAGE and fluorography were carried out on the fractions 
derived  from the DEAE-cellulose column (Fig.  2).  Compo- 
nent A (Fig.  1 b) yielded a single polypeptide, migrating at a 
position corresponding to a molecular weight of 13,000 (Fig. 
2,  lane  2).  Identical  results  were  obtained  irrespective  of 
whether the PAGE was carried out under reducing (with B- 
mercaptoethanol) or nonreducing conditions  (Fig.  3A).  In 
addition to fluorography, we have also subjected the polyac- 
rylamide  gel  to  staining  with  the  silver  technique.  Again, 
component A yielded predominantly a single polypeptide of 
Mr  13,000 (Fig.  3 B, lane 2). Using known amounts of cyto- 
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Figure  1.  Ion-exchange  chromatography  of  a  [35S]methionine-la- 
beled FGR-s preparation (1.5  x  106 cpm) on a column (0.8  x  2 cm) 
of DEAE-cellulose equilibrated with 5 mM Tris, pH 8.0. At the point 
indicated by the arrow, a linear gradient (0-0.5 M NaCI, 100 ml total 
volume) was used to elute the material bound in the column.  17-ml 
fractions were collected. (a) Profile of the growth inhibitory activity 
assayed by the inhibition of [3H]thymidine incorporation into target 
cells. The data on the ordinate axis are expressed as the percentage 
of inhibition relative to control cultures and represent the averages of 
triplicate determinations. (b)  Profile of the protein content assayed 
by counting the radioactivity due to [asS]methionine.  The horizontal 
bars marked A-F denote the fractions that were pooled for further 
analysis. 
chrome c (Mr  12,500)  as a  standard  for the silver staining 
technique, we estimated that  1 liter of conditioned medium 
derived from 3T3 cultures yielded ~ 1 ~g of the  13-kD poly- 
peptide. The material in component A (Fig.  1  b) is designated 
FGR-s ( 13 K). 
Depletion of Growth Inhibitory Activity from FGR-s 
(1310 on an Affinity Column Containing 
Antibody 2,4 4 
To show that the Mr 13,000 polypeptide was directly respon- 
sible for the biological activity, we attempted to deplete, using 
an  affinity  column  containing  antibody  2A4,  the  growth 
inhibitory activity of  preparation of  FGR-s (13K). The affinity 
column was prepared by first coupling the immunoglobulin 
fraction of  rabbit antibodies directed against rat immunoglob- 
ulin to Affi-Gel 10. This derivatized gel was used to prepare 
two different columns in the following ways: (a) the super- 
natant of hybridoma clone 2A4 was passed over one column 
to bind antibody 2A4 (antibody 2A4 column); and (b)  the 
supernatant of  parent myeloma NS-1 cell line was passed over 
the other column (NS-1 control column). Finally, a prepara- 
tion of FGR-s (13K) was percolated through either the anti- 
body 2A4 column or the NS- 1 control column. The activities 
of the original FGR-s (13K) preparation as well as the flow- 
through fractions (representing unbound material) of  the two 
respective affinity columns were compared in growth inhibi- 
tion assays. 
The results showed that the growth inhibitory activity of 
FGR-s (13K) was depleted in the material passed through the 
antibody 2A4 column (Fig, 4). In contrast, the NS-1 control 
column  had  little effect on the  growth  inhibitory activity. 
These results, in conjunction with the previous demonstration 
that  antibody 2A4  affinity columns deplete  FGR-s  of the 
13,000-kD polypeptide, strongly suggest that FGR-s (13K) is 
Figure  2.  SDS  PAGE of a  [3sS]- 
methionine-labeled preparation of 
FGR-s  and  components  derived 
from  fractionation  of  FGR-s  by 
ion-exchange  chromatography 
(Fig.  1).  The  acrylamide concen- 
tration of  the running gel was 16%. 
The samples applied to the gel con- 
rained  ¢~-mercaptoethanol  (4% 
vol/vol).  Approximately  5,000 
cpm were applied to each lane, and 
the radioactive polypeptides were 
revealed by fluorography (2 d  ex- 
posure). Lanes I and 2 were devel- 
oped  on  a  different  fluorogram 
than  the  remainder  of the  lanes. 
The  arrows  indicate  positions  of 
migration of molecular weight (in 
thousands)  markers.  Lanes:  1, 
[aSS]methionine-labeled  FGR-s; 2, 
fraction 6, 3, fraction 9; 4. fraction 
15; 5,  fraction 21; 6,  fraction 27; 
7,  fraction  29;  8,  fraction  33;  9, 
fraction  35;  10,  fraction  38;  11, 
fraction  46;  12,  fraction  52;  13, 
fraction  57;  14,  fraction  68.  All 
fractions refer to those fractions in 
Fig.  lb. 
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of FGR-s (13K) under nonreducing (lane 1) and reducing (4%  vol/ 
vol, 2-mercaptoethanol, lane 2) conditions, The acrylamide concen- 
tration of the running gel was  16%. Approximately 2,000 cpm were 
applied to each lane, and the radioactive polypeptides were revealed 
by fluorography (14 d). (B) Analysis of the polypeptide conpositions 
of FGR-s (lane 1) and FGR-s (13K) (lane 2) by the silver staining 
technique after SDS gel electrophoresis.  The acrylamide concentra- 
tion of the  running gel  was  16%.  The samples applied to the gel 
contained 2-mercaptoethanol (4% vol/vol). 
directly responsible for the observed growth inhibitory activ- 
ity.  The  data  also  argue against  any  indirect  mechanisms, 
such as antibody 2A4 stimulating a growth factor receptor, in 
the  observed neutralization  of FGR-s effects in  the growth 
inhibition assays (8). 
Therefore, FGR-s (13K) contains a single polypeptide (M, 
13,000)  and exhibits growth inhibitory activity. We can now 
conclude that this Mr 13,000  polypeptide is active in growth 
inhibition  assays independent  of the  presence of any other 
polypeptide. Moreover, the other polypeptides do not appear 
to contain growth inhibitory activity inasmuch as the remain- 
der of the fractions from the DEAE-cellulose column (com- 
ponents B-F, Fig.  1 b) failed to show activity. 
The Effects of  FGR-s (13K) on Target Cells: Dose- 
Response,  Viability, and Reversibility 
The inhibitory effect of FGR-s (13K) on  [3H]thymidine in- 
corporation into target cells was dependent on the concentra- 
tion of ligand added (Fig.  5). Over the concentration range of 
0.1-10  ng/ml, there was a  monotonic increase in inhibitory 
activity with increasing concentration of FGR-s (13K) added 
to the cultures.  The concentration of inhibitor required for 
50% inhibition was ~3 ng/ml (Fig. 5, inset). 
Three series of experiments were performed to  ascertain 
that the inhibition of [3H]thymidine incorporation in target 
cells by FGR-s (13K) was due to a  true suppression of cell 
growth rather than to any cytotoxic effects of the inhibitory 
fractions. First, the viabilities of the cells,  assayed by trypan 
blue exclusion tests, were identical for target cultures treated 
with FGR-s (l 3K) and with a control fraction from the DEAE- 
cellulose column. Second, to demonstrate that the inhibitory 
effect of FGR-s on  DNA  synthesis was reversible,  parallel 
cultures were treated with FGR-s (13K) for 22 h. The medium 
was then removed and replaced with an equal volume of fresh 
growth medium. At various times thereafter, DNA synthesis 
was assayed by the incorporation of [3H]thymidine. The data 
showed that the  inhibition was reversible within  20 h  after 
the removal of FGR-s (13K) (Fig. 6). Taken together with the 
demonstration that the viability of target cells was not affected 
by FGR-s, these results suggest that the inhibitory activity of 
FGR-s cannot be ascribed to cytotoxicity. 
Finally, the inhibitory effect of FGR-s (13K) on cell prolif- 
eration is also reflected in assays of  cell number after treatment 
with the  inhibitory fraction.  Target cultures  treated with  a 
control fraction continued to proliferate; in contrast, cultures 
treated with FGR-s (t3K) failed to increase in cell number at 
the same rate (Fig.  7). These data provide a confirmation of 
the growth inhibitory activity of FGR-s (13K) using an assay 
that is independent of [3H]thymidine incorporation. 
The Effects of  FGR-s (13K) on Target Cells: Density 
and Serum Dependence 
In this series of experiments, the effect of varying conditions 
of the assay during the period of exposure of target cells  to 
FGR-s (13K)  was tested  using  a  single  preparation  of the 
inhibitor. The effect of variation in the density of the target 
cells on the inhibition by FGR-s (13K) is shown in Fig. 8. At 
target  cell  densities  of_>5  x  103  cells/cm  2,  the  inhibitory 
activity of FGR-s (13K) was consistently observed. In con- 
trast, when the density of the target cells was <2.5 x  103 cells/ 
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Figure  4.  Depletion of  the growth inhibitory  activity ofFGR-s (13K) 
by an antibody 2A4 column. Affinity columns (0.4 x  2.5 cm) were 
prepared by coupling rabbit anti-rat immunoglobulin  to Affi-Gel 10, 
The supernatant (50 ml) ofhybridoma clone 2A4 or parent myeloma 
line NS- 1  was passed over the affinity column. A preparation of  FGR- 
s (13K) (8 ng/ml, 2 ml) was percolated through these affinity columns. 
The growth inhibitory activities of the flow-through fractions were 
compared with those of the original FGR-s (13K) preparation (Ori) 
and control cultures treated with DME (Ctl). The data are expressed 
in terms of [3H]thymidine ([3H] dT) incorporation into target cells 
and represent the averages of triplicate determinations (___ standard 
error of the mean). 
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Figure  5.  Dose-response  curve  of the  growth  inhibitory activity  of FGR-s  (13K)  on  target  3T3  cells (2  x  104  cells/cm:).  The  protein 
concentration of FGR-s (13K) was determined by the silver staining technique on SDS gels. The target cells were treated with FGR-s (13K) for 
20 h and then assayed for the incorporation of [3H]thymidine ([3HI dT) as described in Materials and Methods. The data represent the averages 
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Figure  6.  The reversibility of the 
effect of FGR-s (13K) on 3T3 cells. 
Target  cells  (5  x  103  cells/cm  2) 
were treated with FGR-s (13K) (3 
ng/ml). The kinetics of DNA syn- 
thesis, assayed by thymidine incor- 
poration  and  expressed  as  a  per- 
cent of control cultures is  shown 
by the solid line. The dotted  line 
indicates the level of DNA synthe- 
sis in cultures after the removal of 
FGR-s  (13K),  relative to  control 
cultures, which also received a me- 
dium change. 
The Journal of Cell Biology. Volume 102, 1986  366 (13K) to inhibit 3T3 cells growth. This is consistent with our 
previous observation that a minimum target cell density may 
be required  before the  inhibitory effect of conditioned  me- 
dium on cell proliferation can be observed (20). 
The growth inhibitory activity of FGR-s (13K) was depend- 
ent on the serum concentration used in the assay (Fig. 9).  In 
the present experiment, FGR-s (13K) (8 ng/ml) yielded -20% 
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Figure  7.  The kinetics of the increase in cell density of 3T3 cultures 
in the presence of  FGR-s (13K) and control. At various times, parallel 
cultures were try.  psinized and the cells were collected for the deter- 
mination of the total cell number in the cultures. Data points are the 
averages of quadruplicate  determinations  (___ standard  error of the 
mean). 
decreasing serum  concentration,  the same concentration of 
FGR-s (13K) exhibited higher levels of growth inhibition (Fig. 
9).  In previous experiments,  we showed that the binding of 
[35S]methionine-labeled FGR-s was inhibited  by serum (25). 
Therefore, the present result, showing higher levels of activity 
of FGR-s (13K) as a function of decreasing concentration of 
serum,  would  be  expected  on  the  basis  of higher  levels  of 
binding of the inhibitor. 
Discussion 
The  key conclusion  derived  from the  present  study is  that 
FGR-s (l 3K) exhibits growth inhibitory activity. In previous 
studies  (8,  26),  we  had  generated  a  monoclonal  antibody 
(2A4) that specifically bound FGR-s (l 3K). This monoclonal 
antibody also neutralized the growth inhibitory activity of the 
partially purified FGR-s fraction. We inferred, therefore, that 
FGR-s  (13K)  must  be  at  least  partly  responsible  for  the 
biological activity. The present results on the purification of 
FGR-s (13K) and the demonstration of its biological activity 
indicate that this polypeptide can exhibit growth inhibitory 
activity independent of the presence of any other polypeptide. 
The main features of the inhibition of 3T3 cell proliferation 
by FGR-s (13K) include: (a) The dose response curve indicates 
that 50% inhibition is obtained at a concentration of-3  ng/ 
ml. corresponding to 0.23 riM. (b) The effect of FGR-s (13K) 
on 3T3 cells is reversible and cannot be ascribed to cytotox- 
icity. (c) The effect of FGR-s (13K) on DNA synthesis was 
most  prominent  at  high  (>5  x  103  cells/cm 2)  target  cell 
density,  consistent  with  previous  observations,  made  with 
conditioned medium (20), that a minimum target cell density 
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Figure  8.  The  effect  of  varying 
the  density  of the target  cells on 
the  inhibitory  activity  of FGR-s 
(13K).  Treatment  of target  cells 
seeded at different  densities  with 
FGR-s (13K) for 24 h was lbllowed 
by a  3-h  pulse  of [3H]thymidine 
([31t] dT).  Data points  represent 
the averages of triplicate determi- 
nations  (+  standard  error of the 
mean). 
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Figure 9.  The effect of  serum concentration  on the growth inhibitory 
activity of FGR-s (13K) assayed on target 3T3  cells (2  x  104 cells/ 
cm2). The target cells were treated with FGR-s (13K) for 24 h in the 
presence of different concentrations of calf serum. The cells were 
pulsed with [3H]thymidine  ([3HI dT) for 3 h. Data points represent 
the averages of triplicate determinations (_+ standard error of the 
mean). 
may be  required to  observe the  inhibitory effect.  (d)  The 
inhibition by FGR-s (13K) on 3T3 cells was most potent at 
low (<5%) serum concentrations, in agreement with previous 
results that the binding of radioactive FGR-s was decreased 
by increasing concentrations of serum (25). 
Analysis of the molecular properties of FGR-s (13K) indi- 
cates that it is active as a single polypeptide (Mr 13,000). This 
polypeptide remains as a monomer in SDS gel electrophoresis 
under both reducing and nonreducing conditions. Moreover, 
FGR-s (13K) migrates on gel filtration columns at a position 
corresponding to a molecular weight of 13,000.  This infor- 
mation is useful in a comparison of the properties of FGR-s 
(13K) with corresponding properties of other negative regu- 
lators of cell growth. 
Tucker et al.  (23)  have recently shown that transforming 
growth factor-~ (TGF-13)  and a growth inhibitor isolated from 
conditioned medium of African green monkey kidney epithe- 
lial cells (BSC-1) shared many properties: (a) both have Mr's 
of 25,000 under nonreducing, nondenaturing conditions and 
Mr's of 12,500  under reducing SDS gels (1, 7, 24); (b) both 
TGF-13 and  the  BSC-I  growth  inhibitor  stimulate  colony 
growth of  AKR-2B cells in soft agar; (c) both molecules inhibit 
the monolayer growth of  a variety of  cell types including BSC- 
1, AKR-2B, and mink lung (CLL64) cells; and (d) both appear 
to  compete  for the  same  receptors on  the  cell  surface  of 
responsive cells.  Therefore, it appears that TGF-8 and the 
BSC- 1 growth inhibitor may be similar if not identical mole- 
cules (23). Corroborating these results, Roberts et al. (18) have 
reported that TGF-i3 is a bifunctional molecule, acting either 
as  a  growth  stimulatory  factor or  as  a  growth  inhibitory 
molecule. The conditions that determine which of these two 
activities is expressed is not solely dependent on the cell type 
or the condition of anchorage-dependent versus anchorage- 
independent growth but is also modulated by the action of 
other growth factors (and their receptors) that may be present 
(18). TGF-13  has been purified to homogeneity, and, therefore, 
it stands as a paradigm for negative regulators of cell growth 
and autocrine regulation. 
Our present results on the  purification of FGR-s (13K) 
suggests that it may join TGF-13 as another example of nega- 
tive  regulator that  functions in  an  autocrine  pathway.  In 
comparing  the  properties  of FGR-s  (13K)  and  TGF-13 it 
should be noted that the latter is active as a dimer (Mr 25,000) 
under nonreducing conditions. Upon reduction, the polypep- 
tide molecular weight of TGF-/~ becomes  12,500,  and the 
biological  activity  (stimulation  of anchorage  independent 
growth in soft agar cultures) is lost (1, 24). In contrast, FGR- 
s (13K) is active as a single polypeptide (Mr 13,000), as noted 
earlier. 
Using procedures similar to our previous studies (19,  20), 
Wells and Malucci (28) have shown that secondary cultures 
of  mouse embryo fibroblasts release into the medium a growth 
inhibitory activity whose physicochemical behavior and poly- 
peptide  composition closely parallel  those  of FGR-s.  The 
molecular weights of the polypeptides in their active fractions 
were  11,000  and  14,000.  In  this  connection, it should be 
noted that both  soluble and  plasma  membrane-associated 
growth inhibitory fractions, derived from 3T3 cells and with 
properties similar to FGR-s have been reported by several 
laboratories (6, 16, 17, 29). The molecular properties of these 
active fractions and their relationship to FGR-s (13K) remain 
to be elucidated. 
Three additional  growth  inhibitory  activities  have  been 
characterized. (a)  A  hepatocyte proliferation inhibitor has 
been purified from rat liver; this inhibitor yielded a polypep- 
tide (Mr 26,000) in SDS gels under reducing conditions and 
an isoelectric point of 4.56 (13,  14). It reversibly inhibited the 
proliferation of nonmalignant rat liver cells  in culture but 
exerted no effect on the proliferation of hepatoma cells. (b) A 
glycopeptide fraction that inhibits protein synthesis and cell 
growth of normal but not transformed cells has been partially 
purified from bovine cerebral cortex cells (10). This prepara- 
tion contained polypeptides of molecular weights  18,000 and 
16,000. (c) Finally, a growth inhibitor (Mr 13,000) for Ehrlich 
ascites mammary carcinoma cells has been purified from the 
bovine  mammary  gland  (2).  Polyclonal  antiserum  raised 
against the inhibitor immunoprecipitated the Mr 13,000 poly- 
peptide and neutralized its growth inhibitory activity as well 
(3). It is quite striking that the constituent polypeptide chains 
of  several  growth  inhibitors  have  molecular  weights  of 
13,000 and 26,000. Perhaps a family of growth inhibitors 
may be defined when structural information becomes avail- 
able for this list of negative regulators of cell growth. 
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